Prof. Ho’s Laboratory is featured on POZ.com, an influential print and online brand for people living with and affected by HIV/AIDS.
Highlighting pivotal developments in HIV treatment from 2023, the article echoes the findings of Perazzolo and colleagues at University of Washington TLC-ART program led by Prfo Ho. Their research introduces a groundbreaking long-acting injectable blend of tenofovir, lamivudine, and dolutegravir, proven effective for a month in primate studies. Leveraging cutting-edge nanoparticle technology, this formulation presents an accessible, possibly self-administered solution, marking a significant stride in enhancing HIV treatment and compliance, with particular promise for resource-limited settings.
https://www.poz.com/article/longerlasting-hiv-meds-horizon
